D.E. Shaw & Co
YMAB

D.E. Shaw & Co’s Y-mAbs Therapeutics YMAB Stock Holding History

D.E. Shaw & Co’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-516,857
Closed -$2.33M – 4982
2025
Q2 		$2.33M Sell
516,857
-32,809
-6% -$147K ﹤0.01% 2627
2025
Q1 		$2.44M Sell
549,666
-65,465
-11% -$380K ﹤0.01% 2463
2024
Q4 		$4.82M Sell
615,131
-172,405
-22% -$2.1M ﹤0.01% 2019
2024
Q3 		$10.4M Sell
787,536
-138,921
-15% -$1.76M 0.01% 1411
2024
Q2 		$11.2M Sell
926,457
-141,702
-13% -$1.91M 0.01% 1264
2024
Q1 		$17.4M Sell
1,068,159
-255,621
-19% -$3.45M 0.01% 1000
2023
Q4 		$9.03M Sell
1,323,780
-25,430
-2% -$147K 0.01% 1442
2023
Q3 		$7.35M Buy
1,349,210
+73,813
+6% +$430K 0.01% 1496
2023
Q2 		$8.66M Buy
1,275,397
+484,441
+61% +$3.63M 0.01% 1458
2023
Q1 		$3.96M Buy
790,956
+322,292
+69% +$1.32M ﹤0.01% 2148
2022
Q4 		$2.29M Buy
468,664
+353,174
+306% +$2.57M ﹤0.01% 2828
2022
Q3 		$1.67M Buy
115,490
+74,103
+179% +$1.23M ﹤0.01% 3159
2022
Q2 		$626K Sell
41,387
-97,270
-70% -$1.13M ﹤0.01% 3964
2022
Q1 		$1.65M Buy
+138,657
New +$1.42M ﹤0.01% 3498
2021
Q3 		– Sell
-39,083
Closed -$1.32M – 5282
2021
Q2 		$1.32M Sell
39,083
-41,382
-51% -$1.33M ﹤0.01% 3317
2021
Q1 		$2.43M Buy
80,465
+25,422
+46% +$1.04M ﹤0.01% 2431
2020
Q4 		$2.73M Buy
55,043
+43,303
+369% +$2M ﹤0.01% 2349
2020
Q3 		$451K Sell
11,740
-19,996
-63% -$796K ﹤0.01% 3277
2020
Q2 		$1.37M Buy
31,736
+11,236
+55% +$425K ﹤0.01% 2703
2020
Q1 		$535K Sell
20,500
-28,928
-59% -$840K ﹤0.01% 3176
2019
Q4 		$1.54M Buy
+49,428
New +$1.46M ﹤0.01% 2677

Other funds holding YMAB

BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

D.E. Shaw & Co's YMAB Position: Q3 2025 in Review

D.E. Shaw & Co sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 516,857 shares — an estimated $2.33M sold.

D.E. Shaw & Co first reported a position in YMAB in Q4 2019 and held it in 21 quarters. The position peaked at $17.4M in Q1 2024. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.

  • D.E. Shaw & Co reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
  • D.E. Shaw & Co sold 516,857 Y-mAbs Therapeutics shares in Q3 2025, an estimated $2.33M.
  • D.E. Shaw & Co first reported a position in Y-mAbs Therapeutics in Q4 2019 and held it in 21 quarters.
  • D.E. Shaw & Co's Y-mAbs Therapeutics position peaked at $17.4M in Q1 2024.
  • 2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.

Based on D.E. Shaw & Co's 13F filing for Q3 2025, filed 14 Nov 2025.